Gilead
Gilead makes $567m strategic acquisition for next-gen CAR-T
December 8, 2017Medical Communications, Sales and Marketing CAR-T, Cell Design Labs, Gilead, Kite, biotech, drugs, pharma, pharmaceutical
It’s only four months since Gilead completed its buy-out of Kite Pharma for $11.9 billion, but it’s already moving quickly …
Gilead launches hep C drug Sovaldi in China at one-fifth of US price
November 29, 2017Research and Development, Sales and Marketing China, Gilead, hepatitis C, pharma, sovaldi
Gilead has officially launched its hepatitis C drug Sovaldi (sofosbuvir) in the Chinese market, but with one major caveat: it …
Learning lessons from HIV to change the treatment access landscape
November 23, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, HIV, pharma
Greg Alton, Executive Vice President of Corporate and Medical Affairs at Gilead, reveals how the rapid development and distribution of …
FDA approves first-ever two-drug HIV regimen, GSK’s Juluca
November 22, 2017Research and Development, Sales and Marketing AIDS, FDA, GSK, Gilead, GlaxoSmithKilne, HIV, Juluca, ViiV Healthcare, pharma
GlaxoSmithKline has announced that the FDA has awarded US marketing authorisation to the first two-drug regimen in the treatment of …
Novartis aims for CAR-T double-approval in Europe
November 6, 2017Sales and Marketing CAR-T, Gilead, Juno, Novartis, biotech, drugs, pharma, pharmaceutical
Just last week Novartis revealed it had applied to the FDA for a new indication in diffuse large B-cell lymphoma …
Novartis reveals the data behind its showdown with Gilead
November 1, 2017Research and Development CAR-T, Gilead, Kymriah, Novartis, biotech, drugs, pharma, pharmaceutical
Only yesterday it was revealed that Novartis had applied to the FDA in the same indication that Gilead’s treatment is …
CAR-T is bringing true precision to the fight against cancer
November 1, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CAR T, CAR-T, Gilead, Kymriah, Novartis, Yescarta
Matt Fellows investigates how the first-ever CAR-T therapy approvals in the past months could mean the field of cancer treatment …
Gilead promotes Alessandro Riva to Senior VP, Hematology and Oncology Therapeutic Area Head
October 24, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, appointment
Gilead had revealed that it has promoted Dr Alessandro Riva, its Senior Vice President, Hematology and Oncology Therapeutic Area Head, …
Gilead gets FDA nod for revolutionary blood cancer treatment
October 19, 2017Sales and Marketing CAR-T, Gilead, Yescarta, biotech, drugs, pharma, pharmaceutical
Only weeks after Gilead announced the completion of Kite, it got the news it was hoping for with the FDA’s …
Gilead completes £11.9 billion Kite Pharma acquisition
October 5, 2017Sales and Marketing CAR T, CAR-T, Gilead, Kite, acquisition, pharma, pharmaceuticals
Gilead has announced that it has completed its acquisition of Kite Pharma after the deal was announced on 28 August …
Gilead’s COO retires, shares take a dive
September 29, 2017Medical Communications Gilead, Kevin Young, biotech, drugs, pharma, pharmaceutical
Gilead has announced that Kevin Young, its Chief Operating Officer, is set to retire from the company in early 2018. …
Anti-HIV drug PrEP proves safety in gay and bisexual adolescents
September 6, 2017Research and Development Gilead, HIV, Pharamceuticals, PrEP, Truvada, health, medicine, pharma
A new study has found that pre-exposure prophylaxis (PrEP) drugs such as Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate), which pre-emptively protects …
Gilead captures Kite in $11.9bn deal
August 29, 2017Manufacturing and Production, Sales and Marketing Gilead, biotech, drugs, kite pharma, pharma, pharmaceutical
Gilead had long been expected to make a serious acquisition to boost flagging growth and it finally made a move …
Gilead set to open $250m, 23-acre campus
August 15, 2017Manufacturing and Production Gilead, biotech, drugs, pharma, pharmaceutical
Gilead is set for the grand unveiling of its new facility in La Verne, Southern California, after several years of …
Nine in 10 people unaware they have hepatitis
July 28, 2017Medical Communications, Research and Development Gilead, biotech, drugs, hepatitis, hepatitis C, pharma, pharmaceutical
The WHO has released a report on the state of hepatitis prevention and treatment to mark World Hepatitis Day, with …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
